Showing results (2591-2600 of 2,777) with videos related to

Sort By:
Pageof 278
Infectious Agents and Cancer|August 8, 2020
HIV and development of epithelial cell abnormalities in women with prior normal cervical cytology in NigeriaJonah Musa, Supriya D Mehta, Chad J Achenbach, et al.
Nature|April 15, 2026
mRNA vaccines engage unconventional pathways in CD8+ T cell primingSuin Jo, Lijin Li, Chandrani Thakur, et al.
JAMA|August 15, 2006
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialRoy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, et al.
The Journal of Infectious Diseases|April 28, 2010
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trialDavid M Asmuth, Robert L Murphy, Susan L Rosenkranz, et al.
Scientific Reports|February 7, 2017
Restenosis Inhibition and Re-differentiation of TGFβ/Smad3-activated Smooth Muscle Cells by ResveratrolYichen Zhu, Toshio Takayama, Bowen Wang, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 8, 2022
Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in referral health centers of Bamako, Mali: What is new?Bourahima Kone, Anou M Somboro, Mahamadou Kone, et al.
JAMA|July 13, 2000
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trialR T Davey, R L Murphy, F M Graziano, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 23, 2001
Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine releaseA M Persico, E Mengual, R Moessner, et al.
Trials|February 26, 2026
Statistical analysis plan for Love Your Brain: a multi-arm randomised controlled trial of a stroke prevention digital platformM F Kilkenny, S L Gall, D A Cadilhac, et al.
Nature|August 14, 2020
cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunityStephen T Ferris, Vivek Durai, Renee Wu, et al.
Pageof 278